Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
543.72B
Market cap543.72B
Price-Earnings ratio
26.08
Price-Earnings ratio26.08
Dividend yield
2.31%
Dividend yield2.31%
Average volume
7.21M
Average volume7.21M
High today
$226.34
High today$226.34
Low today
$222.95
Low today$222.95
Open price
$225.34
Open price$225.34
Volume
7.98M
Volume7.98M
52 Week high
$251.71
52 Week high$251.71
52 Week low
$146.12
52 Week low$146.12

Stock Snapshot

The current Johnson & Johnson(JNJ) stock price is $224.84, with a market capitalization of 543.72B. The stock trades at a price-to-earnings (P/E) ratio of 26.08 and offers a dividend yield of 2.3%.

During the trading session on 2026-05-06, Johnson & Johnson(JNJ) shares reached a daily high of $226.34 and a low of $222.95. At a current price of $224.84, the stock is +0.8% higher than the low and still -0.7% under the high.

Trading volume for Johnson & Johnson(JNJ) stock has reached 7.98M, versus its average volume of 7.21M.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $251.71 and a low of $146.12.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $251.71 and a low of $146.12.

JNJ News

The Motley Fool 7h
Safer Dividend King to Buy Now: AbbVie or Johnson & Johnson?

There are plenty of dividend stocks on equity markets. Few are more secure than Dividend Kings, a group of corporations that have raised their payouts annually...

Safer Dividend King to Buy Now: AbbVie or Johnson & Johnson?
Nasdaq 9h
Is Johnson & Johnson Still the Ultimate Safe Dividend Stock to Buy?

Key Points Johnson & Johnson is a Dividend King, with 64 consecutive years of increases. The company only spent 61% of its free cash flow in 2025 on dividend...

Is Johnson & Johnson Still the Ultimate Safe Dividend Stock to Buy?
Simply Wall St 19h
Ottava Robotic Surgery Milestone Adds New Dimension To Johnson And Johnson

Johnson & Johnson's Ottava Robotic Surgical System has reported its first successful clinical outcomes in complex gastric bypass procedures. The system met pri...

Ottava Robotic Surgery Milestone Adds New Dimension To Johnson And Johnson

Analyst ratings

61%

of 28 ratings
Buy
60.7%
Hold
32.1%
Sell
7.1%

More JNJ News

24/7 Wall St. 1d
Put $5,000 Into This Dividend Giant and Earn Passive Income Every Quarter

Put $5,000 Into This Dividend Giant and Earn Passive Income Every Quarter By Vandita Jadeja Published May 5, 10:50AM EDT Quick Read Johnson & Johnson (JNJ) ge...

Put $5,000 Into This Dividend Giant and Earn Passive Income Every Quarter
TipRanks 2d
Johnson & Johnson announces results from Phase 3 FUZION study of tremfya

Johnson & Johnson announced results from the Phase 3 FUZION study evaluating TREMFYA in adults with active perianal fistulizing Crohn’s disease. At Week 24, TRE...

TipRanks 2d
Johnson & Johnson announces study of OTTAVA System met primary endpoints

Johnson & Johnson announced results from the first clinical study of the investigational OTTAVA Robotic Surgical System. The results were presented at the 2026...

TipRanks 2d
Nanobiotix Fast-Tracks Pivotal Head and Neck Cancer Trial with FDA-Backed Protocol Shift

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Simply Wall St 2d
Assessing Johnson & Johnson Valuation After Fresh FDA Wins In Rare Disease And Neuropsychiatry

Johnson & Johnson (JNJ) stock is drawing fresh attention after the FDA granted Priority Review to IMAAVY for warm autoimmune hemolytic anemia and approved a new...

Assessing Johnson & Johnson Valuation After Fresh FDA Wins In Rare Disease And Neuropsychiatry
Simply Wall St 4d
Pipeline Wins And Dividend Hike Might Change The Case For Investing In Johnson & Johnson

In late April 2026, Johnson & Johnson reported strong first‑quarter results with revenue of US$24.06 billion, raised its full‑year sales outlook to US$100.30–US...

Pipeline Wins And Dividend Hike Might Change The Case For Investing In Johnson & Johnson
Benzinga 5d
S&P 500's Best‑Kept Secret: Why Healthcare Could Be 2026's Breakout Winner

As the S&P 500 seeks the next leg higher, smart money might be moving toward healthcare, a sleeper sector of 2026. Still, the series of earnings upgrades, coupl...

S&P 500's Best‑Kept Secret: Why Healthcare Could Be 2026's Breakout Winner

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.